Search

Search Results

• INFLUENZA AND PNEUMOCOCCAL VACCINATION IN HEMATOLOGICAL MALIGNANCIES: A SYSTEMATIC REVIEW OF EFFICACY, EFFECTIVENESS AND SAFETY

  Giuseppe La Torre

  e2016044

  2016-09-01

  https://doi.org/10.4084/mjhid.2016.044

  4734

  PDF: 1498

  HTML: 3148

• TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML

  Ugo Testa, Dr. Germana Castelli, Dr. Elvira Pelosi

  e2023038

  2023-06-29

  https://doi.org/10.4084/MJHID.2023.038

  2174

  PDF: 1724

  HTML: 384

• MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)

  Ibrahim C. Haznedaroglu

  e2014009

  2013-12-31

  https://doi.org/10.4084/mjhid.2014.009

  4035

  PDF: 1535

  HTML: 9192

  Untitled: 284

  Untitled: 192

  Untitled: 176

  Untitled: 170

  Untitled: 194

  Untitled: 349

• TREATMENT OF INDOLENT AND ADVANCED SYSTEMIC MASTOCYTOSIS Systemic Mastocytosis Treatment

  Alessandro Buonomo, Eleonora Nucera, Marianna Criscuolo

  e2022040

  2022-04-28

  https://doi.org/10.4084/MJHID.2022.040

  2145

  PDF: 1552

  HTML: 513

• CYTOKINE RESPONSE ASSOCIATED WITH HEPATITIS C VIRUS CLEARANCE IN HIV COINFECTED PATIENTS INITIATING PEG INTERFERON-? BASED THERAPY.

  Truong Tam Nguyen, Reihani Niloofar, Pierre-Alain Rubbo, Kuster Nils, Karine Bollore, Jacques Ducos, Georges-Philippe Pageaux, Jacques Reynes, Philippe Van de Perre, Edouard Tuaillon

  e2016003

  2016-01-01

  https://doi.org/10.4084/mjhid.2016.003

  3160

  PDF: 922

  HTML: 2053

  Untitled: 180

• WALDENSTRÖM MACROGLOBULINEMIA - A STATE-OF-THE-ART REVIEW: PART 2- FOCUS ON THERAPY

  Michele Bibas, Shayna Sarosiek , Jorge Castillo

  e2025015

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.015

  2591

  PDF: 2038

  HTML: 224

• OUTCOME OF FRONTLINE TREATMENT WITH “GENERIC” IMATINIB IN ADULT PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN ALGERIAN POPULATION: A MULTICENTER STUDY

  Mohamed Amine BEKADJA

  e2017062

  2017-10-25

  https://doi.org/10.4084/mjhid.2017.062

  2887

  PDF: 741

  HTML: 912

• PROGNOSTIC SIGNIFICANCE OF TRANSCRIPT-TYPE BCR/ABL1 IN CHRONIC MYELOID LEUKEMIA

  matteo molica, elisabetta abruzzese, massimo breccia

  e2020062

  2020-09-12

  https://doi.org/10.4084/mjhid.2020.062

  3859

  PDF: 1618

  HTML: 669

• WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE

  Maddalena Mazzucchelli, Anna Maria Frustaci, Marina Deodato, Roberto Cairoli, Alessandra Tedeschi

  e2018004

  2018-01-01

  https://doi.org/10.4084/mjhid.2018.004

  7672

  PDF: 2448

  HTML: 1742

  Table 1.: 217

  Table 2.: 227

  Table 3.: 211

  Table 4.: 210

• Guest Editor: G. Castaman GENE THERAPY FOR HEMOPHILIA: FACTS AND QUANDARIES IN THE 21ST CENTURY GENE THERAPY FOR HEMOPHILIA

  Bhavya S Doshi, Valder R Arruda, Valder R Arruda

  e2020069

  2020-09-08

  https://doi.org/10.4084/mjhid.2020.069

  2120

  PDF: 1913

  HTML: 353

• RITUXIMAB VERSUS SPLENECTOMY IN CHRONIC PRIMARY ITP: EXPERIENCE OF A SINGLE HEMATOLOGY CLINIC

  Rawanda Shamoon, Ahmed K. Yassin, Sara L. Alnuaimi

  e2024019

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.019

  1281

  PDF: 1169

  HTML: 81

• CAR-T CELL THERAPY IN LARGE B CELL LYMPHOMA CAR-T; Large B Cell Lymphoma; Salvage Therapy,

  Ugo Testa, Giuseppe Leone, Elvira Pelosi, Dr. Germana Castelli, Prof. Hohaus

  e2023066

  2023-10-30

  https://doi.org/10.4084/MJHID.2023.066

  3757

  PDF: 1477

  HTML: 189

• THE GROWING ROLE OF THE BH3 MIMETIC DRUG VENETOCLAX IN THE THERAPY OF ACUTE MYELOID LEUKEMIA

  Elvira Pelosi, Dr. Germana Castelli, Ugo Testa

  e2022080

  2022-10-29

  https://doi.org/10.4084/MJHID.2022.080

  1535

  PDF: 1174

  HTML: 290

• LENALIDOMIDE IN COMBINATION WITH DEXAMETHASONE IN ELDERLY PATIENTS WITH ADVANCED, RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND RENAL FAILURE

  Patrizia Tosi

  e2013037

  2013-06-03

  https://doi.org/10.4084/mjhid.2013.037

  1329

  PDF: 913

  HTML: 1282

  fig 1A: 178

  figure1B: 153

• LIGHT CHAIN AMYLOIDOSIS

  Paolo Milani, Giampaolo Merlini, Giovanni Palladini

  e2018022

  2018-03-01

  https://doi.org/10.4084/mjhid.2018.022

  5881

  PDF: 2348

  HTML: 1337

• TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT Advanced systemic mastocytosis and midostaurin

  Cristina Papayannidis, Vincenzo Federico, Luana Fianchi, Patrizia Pregno, Novella Pugliese, Alessandra Romano, Federica Irene Grifoni

  e2022073

  2022-10-29

  https://doi.org/10.4084/MJHID.2022.073

  1277

  PDF: 1018

  HTML: 226

• IMMUNOLOGY OF TUBERCULOSIS

  Federica Bozzano, Francesco Marras, Andrea De Maria

  e2014027

  2014-04-07

  https://doi.org/10.4084/mjhid.2014.027

  5373

  PDF: 2029

  HTML: 7341

  Untitled: 197

• Antibody response to breakthrough SARS-CoV-2 infection in “booster” vaccinated patients with multiple myeloma according to B/T/NK lymphocyte absolute counts and anti-CD38 treatments

  NICOLA SGHERZA, Anna Mestice, Angela Maria Vittoria Larocca, Pellegrino Musto

  e2024022

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.022

  767

  PDF: 1153

  HTML: 86

• CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF MULTIPLE MYELOMA CAR T Cells and Myeloma Treatment

  Ugo Testa, Elvira Pelosi, Dr. Germana Castelli

  e2024077

  2024-10-31

  https://doi.org/10.4084/MJHID.2024.077

  1762

  PDF: 859

  HTML: 153

• IS THERE A ROLE FOR MINIMAL RESIDUAL DISEASE MONITORING IN FOLLICULAR LYMPHOMA IN THE CHEMO-IMMUNOTHERAPY ERA?

  Giuseppe Gritti, Chiara Pavoni, Alessandro Rambaldi

  e2017010

  2017-01-01

  https://doi.org/10.4084/mjhid.2017.010

  3408

  PDF: 1300

  HTML: 2231

  Fi.1 Gritti.Rambaldi: 210

• CLINICAL SIGNS AND TREATMENT OF NEW-ONSET BONE MARROW FAILURE ASSOCIATED SARS-COV-2 INFECTION IN CHILDREN : A SINGLE INSTITUTION PROSPECTIVE COHORT STUD

  Mervat A M youssef, Ebtisam Shawky hmed, Dalia Tarik Kamal, khalid Elsayh,, Mai A Abdelfatta, Hyam Hassan Mahran Mahran, Mostafa M Embaby

  e2024034

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.034

  1230

  PDF: 1315

  HTML: 124

• “IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY.”

  Sara Martinelli, Antonio Cuneo, Gian Matteo Rigolin

  e2016047

  2016-10-15

  https://doi.org/10.4084/mjhid.2016.047

  4024

  PDF: 1060

  HTML: 3604

  Untitled: 178

  Cneo. Fig.1: 115

  Untitled: 108

  Untitled: 129

  Untitled: 135

• CAR-T CELL THERAPY IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA CAR-T CELL and B-ALL

  Ugo Testa, Prof. Sica, Dr. Pelosi, Dr. Germana Castelli, Prof. Leone

  e2024010

  2024-01-01

  https://doi.org/10.4084/MJHID.2024.010

  4359

  PDF: 3578

  HTML: 221

• MOLECULAR MECHANISMS OF INHIBITOR DEVELOPMENT IN HEMOPHILIA Guest Editor: Giancarlo Costaman

  Davide Matino, Paul Tieu, Dr., Antony Chan

  e2020001

  2020-01-01

  https://doi.org/10.4084/mjhid.2020.001

  3349

  PDF: 1623

  HTML: 449

• TREATMENT OF LOW-BLAST COUNT AML USING HYPOMETHYLATING AGENTS

  Eleonora De Bellis, Luana Fianchi, Francesco Buccisano, Marianna Criscuolo, Luca Maurillo, Laura Cicconi, Mattia Brescini, Maria Ilaria Del Principe, Ambra Di Veroli, Adriano Venditti, Francesco Lo-Coco, Maria Teresa Voso

  e2017045

  2017-07-01

  https://doi.org/10.4084/mjhid.2017.045

  4399

  PDF: 1779

  HTML: 1111

• SYSTEMIC FRONT LINE THERAPY OF FOLLICULAR LYMPHOMA: WHEN, TO WHOM AND HOW

  Francesca Pavanello, Sara Steffanoni, Michele Ghielmini, Emanuele Zucca

  e2016062

  2016-11-06

  https://doi.org/10.4084/mjhid.2016.062

  3787

  PDF: 1076

  HTML: 2066

• The THE PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW: PART 2-FOCUS ON THERAPY

  Michele Bibas

  e2024015

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.015

  1817

  PDF: 1691

  HTML: 898

• Morphologic leukemia-free state after venetoclax-based therapy in acute myeloid leukemia is associated with high relapse despite preserved short-term survival

  Kenta Motegi

  e2026048

  2026-04-30

  https://doi.org/10.4084/MJHID.2026.048

  280

  PDF: 299

  HTML: 22

• PATIENTS WITH HAEMOGLOBINOPATHIES AND CHRONIC HEPATITIS C: A REALLY DIFFICULT TO TREAT POPULATION IN 2016?

  Kalliopi Zachou, Pinelopi Arvaniti, Nikolaos K. Gatselis, Kalliopi Azariadis, Georgia Papadamou, Eirini Rigopoulou, George N. Dalekos

  e2017003

  2017-01-01

  https://doi.org/10.4084/mjhid.2017.003

  2959

  PDF: 993

  HTML: 2066

  Cover letter: 184

• IRON CHELATION THERAPY WITH DEFERASIROX IN THE MANAGEMENT OF IRON OVERLOAD IN PRIMARY MYELOFIBROSIS

  Elena Maria Elli, Angelo Belotti, Andrea Aroldi, Matteo Parma, Pietro Pioltelli, Enrico Maria Pogliani

  e2014042

  2014-05-30

  https://doi.org/10.4084/mjhid.2014.042

  2146

  PDF: 1166

  HTML: 2010

• USE OF HEMATOPOIETIC GROWTH FACTOR IN THE MANAGEMENT OF HEMATOLOGICAL SIDE EFFECTS ASSOCIATED TO ANTIVIRAL TREATMENT FOR HCV HEPATITIS

  Paola Mancino, Katia Falasca, Claudio Ucciferri, Eligio Pizzigallo, Jacopo Vecchiet

  e2010003

  2010-03-26

  https://doi.org/10.4084/mjhid.2010.003

  1131

  PDF: 527

  HTML: 829

• NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES

  Francesco D'Alò, Mariangela Greco, Marianna Criscuolo, Maria Teresa Voso

  e2010021

  2010-08-11

  https://doi.org/10.4084/mjhid.2010.021

  2001

  PDF: 779

  HTML: 702

• DIAMOND BLACKFAN ANEMIA: A TERTIARY CARE CENTRE EXPERIENCE

  avinash kumar singh, tulika seth, nita radhakrishnan, pravas mishra, manoranjan mahapatra, haraprasad pati

  e2013039

  2013-06-03

  https://doi.org/10.4084/mjhid.2013.039

  1838

  PDF: 860

  HTML: 3596

  Diamond Blackfan Anemia: A Tertiary care centre experience: 302

• THERAPEUTIC OPTIONS FOR PATIENTS WHO ARE NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY

  Elihu Estey

  e2013050

  2013-07-12

  https://doi.org/10.4084/mjhid.2013.050

  2190

  PDF: 754

  HTML: 1634

• BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA BLINATUMOMAB and ALL

  Ugo Testa, Elvira Pelosi, Germana Castelli, Patrizia Chiusolo

  e2024070

  2024-08-31

  https://doi.org/10.4084/MJHID.2024.070

  1660

  PDF: 1105

  HTML: 128

• THALIDOMIDE FOR PATIENTS WITH THALASSEMIA INTERMEDIA: A RETROSPECTIVE MULTICENTER CLINICAL STUDY

  Kun Yang, Yi Wu, Yali Zhou, Tianhong Zhou, Li Wang, Zhili Geng, Xiaolin Yin

  e2020021

  2020-04-27

  https://doi.org/10.4084/mjhid.2020.021

  2242

  PDF: 1254

  HTML: 352

• DRUG THERAPY IN THE PROGRESSED CML PATIENT WITH MULTI-TKI FAILURE

  Ibrahim C. Haznedaroglu

  e2015014

  2015-12-02

  https://doi.org/10.4084/mjhid.2015.014

  277703

  PDF: 1813

  HTML: 3875

• INFECTIOUS AETIOLOGY OF MARGINAL ZONE LYMPHOMA AND ROLE OF ANTI-INFECTIVE THERAPY

  Salvatore Perrone, Gianna Maria D'Elia, Alessandro Pulsoni

  e2016006

  2016-01-01

  https://doi.org/10.4084/mjhid.2016.006

  4473

  PDF: 1338

  HTML: 2165

• TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA

  Michele Baccarani, Fausto Castagnetti, Gabriele Gugliotta, Francesca Palandri, Gianantonio Rosti

  e2014005

  2014-01-02

  https://doi.org/10.4084/mjhid.2014.005

  3390

  PDF: 1492

  HTML: 4016

• CLASSICAL HODGKIN LYMPHOMA TODAY

  Francesco D'Alò, Gabriele Schiaffini, Daniele Mazzoni, Eleonora Alma, Flaminia Bellisario, Marcello Viscovo, Elena Maiolo, Silvia Bellesi, Stefan Hohaus

  2026-06-30

  https://doi.org/10.4084/MJHID.2026.055

  337

  PDF: 190

  HTML: 38

• IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW

  Tomasz Sacha

  e2014007

  2013-12-31

  https://doi.org/10.4084/mjhid.2014.007

  4827

  PDF: 2873

  HTML: 2312

• SEPSIS-ASSOCIATED DISSEMINATED INTRAVASCULAR COAGULATION AND THROMBOEMBOLIC DISEASE

  Nicola Semeraro, Concetta T. Ammollo, Fabrizio Semeraro, Mario Colucci

  e2010024

  2010-08-06

  https://doi.org/10.4084/mjhid.2010.024

  3393

  PDF: 1791

  HTML: 4566

• THE USE OF MONOCLONAL ANTIBODIES IN THE TREATMENT OF AUTOIMMUNE COMPLICATIONS OF CHRONIC LYMPHOCYTIC LEUKEMIA

  Luca Laurenti

  e2013027

  2013-04-10

  https://doi.org/10.4084/mjhid.2013.027

  2214

  PDF: 1047

  HTML: 2726

• HODGKIN LYMPHOMA IN CHILDREN: A 16-YEAR EXPERIENCE AT THE CHILDREN’S WELFARE TEACHING HOSPITAL OF BAGHDAD, IRAQ

  Anna Maria Testi, Mazin Faisal Al-Jadiry, Maria Luisa Moleti, Stefania Uccini, Amir Fadhil Al-Darraij, Raghad Majid Al-Saeed, Hasanein Habeeb Ghali, Ahmed Hatem Sabhan, Samaher Abdulrazzaq Fadhil, Safaa Abdulelah Al-Badri, Adil Rabeea Alsaadawi, Ameer Dh Hameedi, Manhal Hashim Shanshal, Yasir Saadoon Al-Agele, Fatimah Abdul Ridha Al-Saffar, Nihal Khalid Yaseen, Alfonso Piciocchi, Giovanni Marsili, Salma Abbas Al-Hadad

  e2024053

  2024-06-29

  https://doi.org/10.4084/MJHID.2024.053

  1053

  PDF: 945

  Suppl. Files: 596

  HTML: 90

• Bortezomib maintenance for the treatment of Monoclonal Gammopathy of Renal Significance

  Holly Lee, Peter Duggan, Ernesta Paola Neri, Jason Tay, Victor Jimenez Zepeda

  e2019007

  2019-01-01

  https://doi.org/10.4084/mjhid.2019.007

  2227

  PDF: 1187

  HTML: 343

• NATION-WIDE SURVEY ON THE USE OF THROMBOPOIETIN RECEPTOR AGONISTS (TPO-RA) FOR THE MANAGEMENT OF IMMUNE THROMBOCYTOPENIA IN CURRENT CLINICAL PRACTICE IN ITALY

  Francesco Rodeghiero, Dr. Mariasanta Napolitano, Nicola Vianelli, Lisanna Ghiotto, Silvia Cantoni, Giuseppe Carli, Monica Carpenedo, Valentina Carrai, Ugo Consoli, Gaetano Giuffrida, Elisa Lucchini, Elena Rossi, Cristina Santoro

  e2023019

  2023-02-28

  https://doi.org/10.4084/MJHID.2023.019

  2050

  PDF: 1241

  PDF Appendix: 689

  HTML: 449

• Azacytidine failure revisited: an appraisal based on real life data from the MDS registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS). Azacytidine failure revisited

  IOANNIS KOTSIANIDIS

  e2019045

  2019-06-25

  https://doi.org/10.4084/mjhid.2019.045

  1106

  PDF: 862

  HTML: 253

• DIFFERENCES IN EX-VIVO CHEMOSENSITIVITY TO ANTHRACYCLINES IN FIRST LINE ACUTE MYELOID LEUKEMIA

  Juan Eduardo Megias-Vericat, David Martínez-Cuadrón, Joaquin Martínez López, Juan Miguel Bergua, Mar Tormo, Josefina Serrano, Ataulfo González, Jaime Pérez de Oteyza, Susana Vives, Belen Vidriales, Pilar Herrera, Juan Antonio Vera, Aurelio López Martínez, Adolfo De la Fuente, María Lourdes Amador, José Ángel Hernández-Rivas, María Ángeles Fernández, Carlos Javier Cerveró, Daniel Morillo, Pilar Hernández Campo, Julián Gorrochategui, Daniel Primo, José Luis Rojas, Margarita Guenova, Joan Ballesteros, Miguel Ángel Sanz, Pau Montesinos

  e2019016

  2019-02-26

  https://doi.org/10.4084/mjhid.2019.016

  1908

  PDF: 1125

  HTML: 261

• APLASTIC ANEMIA AND VIRAL HEPATITIS

  Laura Cudillo

  e2009026

  https://doi.org/10.4084/mjhid.2009.026

  1280

  PDF: 533

  HTML: 23090

• BACTERIAL INFECTIONS FOLLOWING SPLENECTOMY FOR MALIGNANT AND NONMALIGNANT HEMATOLOGIC DISEASES

  Giuseppe Leone, Eligio Pizzigallo

  e2015057

  2015-10-12

  https://doi.org/10.4084/mjhid.2015.057

  4941

  PDF: 1990

  HTML: 8418